A BAFF Receptor His159Tyr Mutation in Sjögren’s Syndrome-Related Lymphoproliferation

Arthritis and Rheumatology

Volumn 67, Issue 10, 2015, Pages 2732-2741

  Papageorgiou, Aristea ^a   Mavragani, Clio P ^a   Nezos, Andrianos ^a   Zintzaras, Elias ^b,d   Quartuccio, Luca ^c   De Vita, Salvatore ^c   Koutsilieris, Michael ^a   Tzioufas, Athanasios G ^a   Moutsopoulos, Haralampos M ^a   Voulgarelis, Michael ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b UNIVERSITY OF THESSALY   (Greece)

^c SANTA MARIA DELLA MISERICORDIA UNIVERSITY HOSPITAL   (Italy)

^d TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B CELL ACTIVATING FACTOR RECEPTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN;

ADULT; AGED; ARTHRITIS, RHEUMATOID; CASE CONTROL STUDY; COMPLICATION; FEMALE; GENETIC PREDISPOSITION; GENETICS; HETEROZYGOTE; HUMAN; LUPUS ERYTHEMATOSUS, SYSTEMIC; LYMPHOPROLIFERATIVE DISORDERS; MALE; MARGINAL ZONE LYMPHOMA; MIDDLE AGED; MUTATION; PHYSIOLOGY; PREVALENCE; SIGNAL TRANSDUCTION; SJOGREN'S SYNDROME;

ADULT; AGED; ARTHRITIS, RHEUMATOID; B-CELL ACTIVATION FACTOR RECEPTOR; CASE-CONTROL STUDIES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HETEROZYGOTE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; LYMPHOMA, B-CELL, MARGINAL ZONE; LYMPHOPROLIFERATIVE DISORDERS; MALE; MIDDLE AGED; MUTATION; NF-KAPPA B; PREVALENCE; SIGNAL TRANSDUCTION; SJOGREN'S SYNDROME;

EID: 84988864510     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/ART.39231     Document Type: Article

References (40)

1. Mavragani CP, Moutsopoulos HM. Sjögren’s syndrome. Ann Rev Pathol 2014;9: 273-85.
2. Skopouli FN, Dafni U, Ioannidis JP, Moutsopoulos HM. Clinical evolution, and morbidity and mortality of primary Sjögren’s syndrome. Semin Arthritis Rheum 2000;29: 296-304.
3. Voulgarelis M, Dafni UG, Isenberg DA, Moutsopoulos HM, and the members of the European Concerted Action on Sjögren’s Syndrome. Malignant lymphoma in primary Sjögren’s syndrome: A multicenter, retrospective, clinical study by the European Concerted Action on Sjögren’s Syndrome. Arthritis Rheum 1999;42: 1765-72.
4. Ioannidis JP, Vassiliou VA, Moutsopoulos HM. Long-term risk of mortality and lymphoproliferative disease and predictive classification of primary Sjögren’s syndrome. Arthritis Rheum 2002; 46:741-7.
5. Tzioufas AG, Boumba DS, Skopouli FN, Moutsopoulos HM. Mixed monoclonal cryoglobulinemia and monoclonal rheumatoid factor cross-reactive idiotypes as predictive factors for the development of lymphoma in primary Sjögren’s syndrome. Arthritis Rheum 1996;39:767-72.
6. Theander E, Vasaitis L, Baecklund E, Nordmark G, Warfvinge G, Liedholm R, et al. Lymphoid organisation in labial salivary gland biopsies is a possible predictor for the development of malignant lymphoma in primary Sjögren’s syndrome. Ann Rheum Dis 2011;70:1363-8.
7. Papageorgiou A, Ziogas DC, Mavragani CP, Zintzaras E, Tzioufas AG, Moutsopoulos HM, et al. Predicting the outcome of Sjögren’s syndrome-associated non-Hodgkin’s lymphoma patients. PloS One 2015;10: E0116189.
8. Mariette X. Lymphomas complicating Sjögren’s syndrome and hepatitis C virus infection may share a common pathogenesis: Chronic stimulation of rheumatoid factor B cells. Ann Rheum Dis 2001;60:1007-10.
9. Pisa EK, Pisa P, Kang HI, Fox RI. High frequency of t(14;18) translocation in salivary gland lymphomas from Sjögren’s syndrome patients. J Exp Med 1991;174:1245-50.
10. Tapinos NI, Polihronis M, Moutsopoulos HM. Lymphoma development in Sjögren’s syndrome: Novel p53 mutations. Arthritis Rheum 1999;42:1466-72.
11. Nezos A, Papageorgiou A, Fragoulis G, Ioakeimidis D, Koutsilieris M, Tzioufas AG, et al. B-cell activating factor genetic variants in lymphomagenesis associated with primary Sjögren’s syndrome. J Autoimmun 2014;51:89-98.
12. Nocturne G, Boudaoud S, Miceli-Richard C, Viengchareun S, Lazure T, Nititham J, et al. Germline and somatic genetic variations of TNFAIP3 in lymphoma complicating primary Sjögren’s syndrome. Blood 2013;122:4068-76.
13. Ferrer G, Hodgson K, Montserrat E, Moreno C. B cell activator factor and a proliferation-inducing ligand at the cross-road of chronic lymphocytic leukemia and autoimmunity. Leuk Lymphoma 2009;50:1075-82.
14. Rothman N, Skibola CF, Wang SS, Morgan G, Lan Q, Smith MT, et al. Genetic variation in TNF and IL10 and risk of non-Hodgkin lymphoma: A report from the InterLymph Consortium. Lancet Oncol 2006;7:27-38.
15. Juszczynski P, Kalinka E, Bienvenu J, Woszczek G, Borowiec M, Robak T, et al. Human leukocyte antigens class II and tumor necrosis factor genetic polymorphisms are independent predictors of non-Hodgkin lymphoma outcome. Blood 2002;100:3037-40.
16. Demeter J, Porzsolt F, Ramisch S, Schmidt D, Schmid M, Messer G. Polymorphism of the tumour necrosis factor-a and lymphotoxin-a genes in chronic lymphocytic leukaemia. Br J Haematol 1997;97:107-12.
17. Seror R, Ravaud P, Bowman SJ, Baron G, Tzioufas A, Theander E, et al, on behalf of the EULAR Sjögren’s Task Force. EULAR Sjögren’s Syndrome Disease Activity Index: Development of a consensus systemic disease activity index for primary Sjögren’s syndrome. Ann Rheum Dis 2010;69:1103-9.
18. Quartuccio L, Salvin S, Fabris M, Maset M, Pontarini E, Isola M, et al. BLyS upregulation in Sjögren’s syndrome associated with lymphoproliferative disorders, higher ESSDAI score and B-cell clonal expansion in the salivary glands. Rheumatology (Oxford) 2013;52:276-81.
19. Hildebrand JM, Luo Z, Manske MK, Price-Troska T, Ziesmer SC, Lin W, et al. A BAFF-R mutation associated with non-Hodgkin lymphoma alters TRAF recruitment and reveals new insights into BAFF-R signaling. J Exp Med 2010;207:2569-79.
20. Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE, et al, and the European Study Group on Classification Criteria for Sjögren’s Syndrome. Classification criteria for Sjögren’s syndrome: A revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002;61:554-8.
21. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-7.
22. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd, et al. 2010 rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 2010;62: 2569-81.
23. Jaffe ES. The 2008 WHO classification of lymphomas: Implications for clinical practice and translational research. Hematology Am Soc Hematol Educ Program 2009:523-31.
24. Zintzaras E. The generalized odds ratio as a measure of genetic risk effect in the analysis and meta-analysis of association studies. Stat Appl Genet Mol Biol 2010;9: Article21.
25. Zintzaras E. The power of generalized odds ratio in assessing association in genetic studies with known mode of inheritance. J Appl Stat 2012;39:2569-81.
26. Gottenberg JE, Seror R, Miceli-Richard C, Benessiano J, Devauchelle-Pensec V, Dieude P, et al. Serum levels of beta2-microglobulin and free light chains of immunoglobulins are associated with systemic disease activity in primary Sjögren’s syndrome: Data at enrollment in the prospective ASSESS cohort. PloS One 2013;8:e59868.
27. Tobon GJ, Saraux A, Gottenberg JE, Quartuccio L, Fabris M, Seror R, et al. Role of Fms-like tyrosine kinase 3 ligand as a potential biologic marker of lymphoma in primary Sjögren’s syndrome. Arthritis Rheum 2013;65:3218-27.
28. Sisto M, Lisi S, Lofrumento DD, Ingravallo G, Maiorano E, D’Amore M. A failure of TNFAIP3 negative regulation maintains sustained NF-kB activation in Sjögren’s syndrome. Histochem Cell Biol 2011;135:615-25.
29. Lisi S, Sisto M, Lofrumento DD, D’Amore M. Altered IkBa expression promotes NF-kB activation in monocytes from primary Sjögren’s syndrome patients. Pathology 2012;44:557-61.
30. Peng B, Ling J, Lee AJ, Wang Z, Chang Z, Jin W, et al. Defective feedback regulation of NF-kB underlies Sjögren’s syndrome in mice with mutated kB enhancers of the IkBa promoter. Proc Natl Acad Sci U S A 2010;107:15193-8.
31. Reksten TR, Johnsen SJ, Jonsson MV, Omdal R, Brun JG, Theander E, et al. Genetic associations to germinal centre formation in primary Sjögren’s syndrome. Ann Rheum Dis 2014;73: 1253-8.
32. Nordmark G, Wang C, Vasaitis L, Eriksson P, Theander E, Kvarnstrom M, et al. Association of genes in the NF-kB pathway with antibody-positive primary Sjögren’s syndrome. Scand J Immunol 2013;78:447-54.
33. Mudaliar MA, Haggart RD, Miele G, Sellar G, Tan KA, Goodlad JR, et al. Comparative gene expression profiling identifies common molecular signatures of NF-kB activation in canine and human diffuse large B cell lymphoma (DLBCL). PloS One 2013;8:e72591.
34. Neven B, Mamessier E, Bruneau J, Kaltenbach S, Kotlarz D, Suarez F, et al. A Mendelian predisposition to B-cell lymphoma caused by IL-10R deficiency. Blood 2013;122:3713-22.
35. Baecklund E, Smedby KE, Sutton LA, Askling J, Rosenquist R. Lymphoma development in patients with autoimmune and inflammatory disorders: What are the driving forces? Semin Cancer Biol 2014;24:61-70.
36. Inagaki H. Mucosa-associated lymphoid tissue lymphoma: Molecular pathogenesis and clinicopathological significance. Pathol Int 2007;57:474-84.
37. Zintzaras E, Voulgarelis M, Moutsopoulos HM. The risk of lymphoma development in autoimmune diseases: A meta-analysis. Arch Intern Med 2005;165:2337-44.
38. Ramos-Casals M, Cervera R, Font J, Garcia-Carrasco M, Espinosa G, Reino S, et al. Young onset of primary Sjögren’s syndrome: Clinical and immunological characteristics. Lupus 1998;7: 202-6.
39. Haga HJ, Jonsson R. The influence of age on disease manifestations and serological characteristics in primary Sjögren’s syndrome. Scand J Rheumatol 1999;28:227-32.
40. Voulgarelis M, Ziakas PD, Papageorgiou A, Baimpa E, Tzioufas AG, Moutsopoulos HM. Prognosis and outcome of non-Hodgkin lymphoma in primary Sjogren syndrome. Medicine (Baltimore) 2012;91:1-9.